Back to Newsroom
Back to Newsroom

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Tuesday, 11 June 2024 06:10 PM

Kaskela Law LLC

PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE:PLX) ("Protalix") on behalf of the company's shareholders.

Since May 2023, shares of Protalix common stock have declined in value from a trading price of approximately $3.25 per share to a current trading price of below $1.25 per share, a decline of over 61% in value.

The investigation seeks to determine whether Protalix and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's investors.

Protalix shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 - 0750 or (888) 715 - 1740 for additional information about this investigation and their legal rights and options, or by clicking on the following link (or if necessary, copying and pasting the link into your browser):

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit

D. Seamus Kaskela, Esq.
([email protected])
Adrienne Bell, Esq.
([email protected])
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 - 1740
(484) 229 - 0750

This notice may constitute attorney advertising in certain jurisdictions.

SOURCE: Kaskela Law LLC

Class Action
Back to newsroom
Back to Newsroom

Contact Us Today

If you have questions or want to learn more about our products, our team’s here to help!

Share by: